Robin Harper  Cowie net worth and biography

Robin Cowie Biography and Net Worth

CFO of Biodesix
Robin Harper Cowie has served as our Chief Financial Officer since April 2017. She has been with the Company in multiple financial and reimbursement positions since March 2011, serving as Vice President of Finance from February 2016 to April 2017, Vice President of Reimbursement & Health Economics from February 2015 to February 2016, Senior Director of Reimbursement from January 2014 to February 2015, and Director of Reimbursement from March 2011 to January 2014. Prior to joining Biodesix, Ms. Harper Cowie held a leadership role in payer and government relations at Precision Therapeutics, Inc. Ms. Harper Cowie’s background includes corporate finance, managed care and payer relations, reimbursement and regulatory policy, and revenue cycle operations. Additionally, she spent several years as a researcher at the University of Pittsburgh Medical Center. Ms. Harper Cowie holds a B.S. in Molecular Biology from the University of Pittsburgh, and an M.B.A. in Finance from the Joseph M. Katz Graduate School of Business from the University of Pittsburgh.

What is Robin Harper Cowie's net worth?

The estimated net worth of Robin Harper Cowie is at least $242,256.30 as of February 12th, 2024. Ms. Cowie owns 169,410 shares of Biodesix stock worth more than $242,256 as of March 29th. This net worth evaluation does not reflect any other assets that Ms. Cowie may own. Additionally, Ms. Cowie receives an annual salary of $390,870.00 as CFO at Biodesix. Learn More about Robin Harper Cowie's net worth.

How old is Robin Harper Cowie?

Ms. Cowie is currently 44 years old. There are 2 older executives and no younger executives at Biodesix. The oldest executive at Biodesix is Dr. Gary Anthony Pestano Ph.D., Chief Development Officer, who is 57 years old. Learn More on Robin Harper Cowie's age.

What is Robin Harper Cowie's salary?

As the CFO of Biodesix, Inc., Ms. Cowie earns $390,870.00 per year. The highest earning executive at Biodesix is Mr. Scott Hutton, President, CEO & Director, who commands a salary of $632,000.00 per year. Learn More on Robin Harper Cowie's salary.

How do I contact Robin Harper Cowie?

The corporate mailing address for Ms. Cowie and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on Robin Harper Cowie's contact information.

Has Robin Harper Cowie been buying or selling shares of Biodesix?

Within the last three months, Robin Harper Cowie has sold $33,939.86 in shares of Biodesix stock. Most recently, Robin Harper Cowie sold 8,699 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $1.66, for a transaction totalling $14,440.34. Following the completion of the sale, the chief financial officer now directly owns 169,410 shares of the company's stock, valued at $281,220.60. Learn More on Robin Harper Cowie's trading history.

Who are Biodesix's active insiders?

Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.

Are insiders buying or selling shares of Biodesix?

During the last twelve months, Biodesix insiders bought shares 5 times. They purchased a total of 241,195 shares worth more than $355,841.66. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 123,699 shares worth more than $213,757.05. The most recent insider tranaction occured on February, 12th when CAO Chris Vazquez sold 922 shares worth more than $1,530.52. Insiders at Biodesix own 63.8% of the company. Learn More about insider trades at Biodesix.

Information on this page was last updated on 2/12/2024.

Robin Harper Cowie Insider Trading History at Biodesix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2024Sell8,699$1.66$14,440.34169,410View SEC Filing Icon  
2/9/2024Sell10,156$1.92$19,499.52178,109View SEC Filing Icon  
11/9/2023Sell491$1.27$623.57137,064View SEC Filing Icon  
8/9/2023Sell1,789$1.39$2,486.71133,323View SEC Filing Icon  
5/9/2023Sell2,512$1.57$3,943.84118,338View SEC Filing Icon  
2/9/2023Sell4,220$1.80$7,596.0099,275View SEC Filing Icon  
11/9/2022Sell1,999$1.04$2,078.9676,112View SEC Filing Icon  
8/9/2022Sell3,533$2.53$8,938.4966,537View SEC Filing Icon  
5/10/2022Sell3,338$1.83$6,108.5458,495View SEC Filing Icon  
11/17/2021Buy1,000$6.51$6,510.00View SEC Filing Icon  
See Full Table

Robin Harper Cowie Buying and Selling Activity at Biodesix

This chart shows Robin Harper Cowie's buying and selling at Biodesix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biodesix Company Overview

Biodesix logo
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Read More

Today's Range

Now: $1.43
Low: $1.43
High: $1.48

50 Day Range

MA: $1.65
Low: $1.35
High: $2.12

2 Week Range

Now: $1.43
Low: $1.03
High: $2.21

Volume

24,376 shs

Average Volume

91,099 shs

Market Capitalization

$138.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14